BGLC
BioNexus Gene Lab Corp
Key Financials
Gross Profit
$1.1M
↓ 15.8%
Revenue
$7.4M
↓ 21.9%
Operating Income
$-2965065
↓ 88.4%
Net Income
$-2984607
↓ 86.7%
EPS (Diluted)
$-0.09
↑ 45.8%
Total Assets
$9.3M
↓ 11.3%
Total Liabilities
$637856.00
↓ 69.8%
Shareholders' Equity
$8.6M
↑ 3.5%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13D | 8/14/2026 | View on SEC |
| 4 | 8/14/2026 | View on SEC |
| 4 | 8/14/2026 | View on SEC |
| 4 | 8/14/2026 | View on SEC |
| 4 | 8/14/2026 | View on SEC |
| 4 | 8/14/2026 | View on SEC |
| 10-Q | 8/14/2026 | View on SEC |
| 3 | 8/7/2026 | View on SEC |
| 3 | 7/31/2026 | View on SEC |
| 3 | 7/31/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | BGLC |
| Company Name | BioNexus Gene Lab Corp |
| CIK | 1737523 |
| Sector | Services-Medical Laboratories |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 8071 |
| SIC Description | Services-Medical Laboratories |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | WY |
| Phone | 1-307-241-6898 |